ClinicalTrials.gg
RecruitingNCT06657222Updated Sep 11, 2026

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of TUB-030 in Advanced Solid Tumors, HNSCC and SCLC, sponsored by Tubulis GmbH. Recruiting at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Tubulis GmbH · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
96th of 994
250 · median 41
Started
2024
with 64 others
Phase 1/2
157 of 1,099
39 open now
Primary completion
2028-12
later than 266 of 346 live
Registered
984th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 96th largest by planned enrollment of the 994 interventional ones that give a count, is one of 65 that started in 2024, is one of 157 in phase 1/2, reaches primary completion later than 266 of the 346 other live ones, and was the 984th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are:

To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose.

Participants will:

Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms

03

Conditions studied

  • Advanced Solid Tumors
  • HNSCC
  • SCLC
  • NSCLC
  • TNBC - Triple-Negative Breast Cancer
  • CRC

Keywords

  • Advanced Solid Tumors
  • NSCLC
  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-breastfeeding female aged 18 years or older
  2. Adequate organ function
  3. Patients who received anti-cancer treatment including chemotherapy, biological therapy, endocrine therapy, PARP inhibitor, or other oral or drugs must have had their last dose at least 4 weeks (6 weeks for nitrosourea, mitomycin-C) or 5 half-lives, whichever is shorter, before C1D1
  4. AEs related to prior therapy, radiotherapy or surgical procedures must resolve to ≤grade 1.
  5. For patients with known , evidence of clinically stable disease post radiation therapy is required prior to enrollment.
  6. For patients who underwent radiotherapy (≥ 30% of the bone marrow or wide field) to sites outside the brain, the final dose of radiation must have been administered ≥ 28 days prior to C1D1. For patients who underwent palliative radiotherapy (≤ 30% of the bone marrow or wide field) the final dose of radiation must have been administered ≥14 days prior to C1D1.
  7. Radiologically by v1.1, 4 weeks before C1D1, that can include a lesion in an irradiated field that shows progression according to RECIST v1.1 after irradiation.
  8. (ECOG) 0-1.
  9. Have a of >12 weeks for disease-related mortality, as evaluated by the INV.
  10. In the opinion of the INV, the patient must be able and willing to understand and give signed
  11. Women of (WOCBP) who are sexually active with a non-sterilized partner must use at least 1 highly effective method of (with a failure rate of 1% per year) from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of patients of childbearing potential Patients must agree to continue a highly effective contraceptive method, refrain from egg cell donation and breastfeeding while on study treatment and for 5 half-lives plus 6 months after the last dose of study treatment.
  12. Males must use an effective barrier method of contraception without interruption if the patient is sexually active with an WOCBP until the end of exposure, 5 half-lives plus 6 months add-on after the end of treatment. In addition, their female partners who are WOCBP should agree to use 1 highly effective barrier method of contraception at the same time. Male patients should refrain from donating sperm during study participation and for 6 months after the last dose of the study drug.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Phase 1: dose escalation

    Drug TUB-030, administered by intravenous (IV) infusion

    Drug: TUB-030

  • Experimental
    Phase 2: dose optimization in NSCLC and HNSCC

    Drug TUB-030, administered by intravenous (IV) infusion NSCLC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion HNSCC Cohort: Patients will be randomized to receive one of two doses administered by IV infusion

    Drug: TUB-030

Interventions

  • DrugTUB-030

    A complete treatment cycle is defined as 21 calendar days. TUB-030 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

06

What researchers measure

Primary outcomes

  1. Determination of MTD

    The highest dose is defined at which no more than 1 of 3 patients have had a Dose Limiting Toxicity (DLT) according to NCI CTCAE V5.0 criteria

    Time frame: From enrollment until 30 days after last study drug

Secondary outcomes

  1. Number of patients with Adverse Events (AE)

    Any medical event in a participant which may or may not have a causal relationship with this treatment.

    Time frame: From enrollment until 30 days after last study drug

  2. Maximum concentration (Cmax)

    The concentration of TUB-030 (conjugated ADC), total mAb, and free payload (Cmax will be derived).

    Time frame: From enrollment until 30 days after last study drug

  3. Trough concentration (Cmin)

    The concentration of TUB-030 (conjugated ADC), total mAb, and free payload (Cmin will be derived).

    Time frame: From enrollment until 30 days after last study drug

  4. The time taken to reach the maximum concentration (Tmax)

    The concentration of TUB-030 (conjugated ADC), total mAb, and free payload (Tmax will be derived).

    Time frame: From enrollment until 30 days after last study drug

  5. Area Under Curve (AUC)

    PK endpoint

    Time frame: From enrollment until 30 days after last study drug

  6. Half life (T1/2)

    PK endpoint

    Time frame: From enrollment until 30 days after last study drug

  7. Determination of immunogenicity

    Number and percentage of patients developing anti-TUB-030 antibodies

    Time frame: From enrollment until 30 days after last study drug

  8. Determination of efficacy

    ORR by investigator assest Recist 1.1

    Time frame: From enrolment until 30 days after last study drug.

07

Study locations

19 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2028, 48 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 78. This study's planned 48 months is below that.

Counting every sponsor, half of 137 studies reached it within 61 months; a quarter within 47 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 24, 2024
StartActual
Dec 13, 2024
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06657222
Lead sponsor
Tubulis GmbH
Responsible party
Sponsor
First posted
Oct 24, 2024
Start date
Dec 13, 2024
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Tubulis Clinical Trial Inquiries
Contact
ct-inquiries@tubulis.com
+491758005594
Yariv Houvras, MD, PhD
study director · Tubulis GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion